Leading Edge Genomic Services & Solutions

Novogene Receives CFDA Approval for NovoFocus NSCLC CDx Test

Beijing, China – August 15, 2018 – Tianjin Novogene Bioinformatics Technology Company LTD, a fully-owned subsidiary of Novogene Co., received CFDA approval for its NovoFocus NSCLC CDx Test today. This is a next-generation sequencing (NGS)-based diagnostic test that simultaneously analyzes tumor samples for multiple genomic mutations associated with several CFDA-approved targeted therapies for non-small cell lung cancer (NSCLC), which accounts for ~80% of all lung cancers in China.

The NovoFocus NSCLC CDx Test was developed on the Thermo Fisher Ion Proton™ sequencing platform (approved by CFDA as “DA8600” in January 2017 for the diagnosis of cancer and inherited diseases). The reagent kits for sample processing and library construction, as well as the data analysis and result reporting software system, were developed by Novogene. Following this CFDA approval, results from the sequencing and analysis of three genes, EGFR, ALK and ROS1, can be used to identify NSCLC patients who may be eligible for treatment by CFDA-approved targeted therapies Gefitinib (IRESSA®), Osimertinib (TAGRISSO®) and Crizotinib (XALKORI®), respectively. Results on the other three genes, KRAS, BRAF and PIK3CA, can be considered by clinicians together with other test results and the patient’s disease characteristics during clinical decision making.

Figure: CFDA announcement for the approval of the NovoFocus NSCLC CDx Test (red box: translated to English below)

Ion Proton™ is a registered trademark of Thermo Fisher; IRESSA® and TAGRISSO® are registered trademarks of AstraZeneca; and XALKORI® is a registered trademark of Pfizer.

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit https://en.novogene.com/.

Novogene Receives CLIA Certification for its Clinical Laboratory in Sacramento, California

Sacramento, California – May 1, 2018 – Novogene, a leading global provider of genomic services and solutions, announced that it successfully obtained CLIA certification for its clinical laboratory on March 27, 2018.

The Clinical Laboratory Improvement Amendments (CLIA) are the US federal regulatory standards that apply to US facilities that test human specimens for diagnosis, prevention or treatment of disease or other health assessment. CLIA regulations require clinical laboratories to be certified by their state and the Centers for Medicare and Medicaid Services (CMS) before they can accept human samples for clinical testing. The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) support the regulations of CLIA and play unique roles in assuring quality laboratory testing. An important objective of the CLIA is to ensure the accuracy, reliability and timeliness of clinical test results.

The process of CLIA certification includes inspections of the following: specimen collection, sample transportation, sample preparation and storage, laboratory platforms, assay validation, instrument and reagent calibration, quality assessment and proficiency testing, laboratory biosafety inspection, and onsite audit of laboratory environment, staff, and management system. Novogene’s Sacramento laboratory has passed all the above inspections and demonstrated its assay’s reliable performance.

The CMS also evaluates the performance characteristics of a laboratory’s bioinformatics analysis pipeline. Novogene’s bioinformatics pipeline integrates public data with its in-house database. With its comprehensive database and bioinformatics pipeline, Novogene is able to deliver clinical-grade genomic testing.

According to Dr. David Jiang, General Manager of Clinical and Consumer Genomics at Novogene, “CLIA certification is an important milestone for Novogene, allowing us to provide genomic solutions not only for scientific research, but also for clinical testing. We are excited to offer our clinical partners high-quality sequencing services at low cost with fast turn-around time. Our goal is to democratize sequencing in the clinical space.”

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit https://en.novogene.com.

Contact:
Joyce Peng, Ph.D.
Global Marketing Director and General Manager
San Diego, California
+1-626-222-5584
joyce.peng@novogene.com

The University Medical Center Groningen and Novogene Announce the Start of the 10K Metagenome Project

Groningen, Netherlands and Beijing, China – October 31, 2017 — A research group led by Professor Cisca Wijmenga from the University Medical Center Groningen (UMCG) and Novogene, a leading global provider of genomic services and solutions, today announced a partnership to start the 10K Metagenome Project to further study population-based metagenomics.

The 10K Metagenome Project is initiated by Professor Cisca Wijmenga, Professor Rinse Weersma, Associate Professor Jingyuan Fu, and Associate Professor Alexandra Zhernakova from UMCG. This project aims to analyze 10,000 gut microbiomes from a large, deeply phenotyped population-based cohort in the Netherlands by using next-generation sequencing to study interactions between the microbiome and exogenous and intrinsic host factors. This follows a successful proof of concept study that was published last year in Science (Zhernakova et al., 2016). As part of the partnership, Novogene will provide next-generation sequencing for stool samples collected by UMCG and deliver high-quality data for each metagenome.

“Metagenomic shotgun sequencing allows us to discover intrinsic and exogenous factors that correlate with shifts in the microbiome composition and functionality,” said Professor Cisca Wijmenga, Spinoza Prize winner at UMCG. “Combined with the 8000 phenotypes present in the biobank, this rich dataset will enhance our understanding of which strains and pathways prevent or cause disease, a first step in translational research”.

“By leveraging the largest sequencing capacity in the world as well as our rich experience with next-generation sequencing technology, Novogene is taking an active role in accelerating genomic studies from all over the world,” said Ms. Tingting Zhou, General Manager of Novogene Europe. “It’s a great honor to partner with distinguished scholars from UMCG on the 10K Metagenome Project. This unprecedented study will shed more light on gut metagenomics, and therefore provide a better understanding of human health. We are proud to be part of it.”

About UMCG
The University Medical Center Groningen (UMCG) was established in 2005 as a joint activity of the University of Groningen and the Academic Hospital Groningen (AZG). At present, the UMCG is one of the largest hospitals in the Netherlands and the largest employer in the Northern Netherlands. More than 12,000 employees provide patient care, are involved in medical education and performing cutting-edge scientific research, and are focused on “healthy and active aging”.

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit https://en.novogene.com/.

Contact:

Professor Cisca Wijmenga, UMCG
C.Wijmenga@umcg.nl

Professor Rinse Weersma, UMCG
r.k.weersma@umcg.nl

Weiyan Peng
Business Development Director
Novogene Europe
pengweiyan@novogene.com

Novogene NGS Medical Lab Receives CAP Accreditation

April 4, 2017, San Diego and Beijing — Novogene Corporation, a leading provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise, today announced that its next-generation sequencing (NGS) medical lab in Tianjin, China has received accreditation from the College of American Pathologists (CAP). With CAP accreditation, Novogene now will be able to provide its high-quality, well-established clinical sequencing services to customers throughout the world.

The process of CAP accreditation involves a rigorous series of inspections and certifications on lab quality management systems, experimental processes, data analysis and clinical interpretation. CAP accreditation, received on March 30th, 2017, attests to Novogene Tianjin medical lab’s global comparability and competitiveness for NGS sample quality control, personnel qualification, facilities, and quality assurance.

Novogene established its clinical service division in January 2014, and has continuously developed its clinical services in China, including tumor gene detection and genetic testing services. Novogene also established a Precision Medicine Center of Excellence with Thermo Fisher Scientific in December 2016 and is one of the first China National Genetic Testing Technology Demonstration Centers.

“Our strategy is to incorporate scientific research, clinical diagnostics, and preventive medicine synergistically to drive life science research and improve human healthcare,” stated Dr. Ruiqiang Li, CEO of Novogene. “CAP accreditation represents an important milestone for our Tianjin medical center, which can now provide superior clinical services to our more than 450 hospital customers and pharmaceutical partners globally for projects of any scale, in ways that we could not before.”

About Novogene Corporation
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacities in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,300 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top tier journals such as Nature and Science, the company has rapidly become a world-leader in NGS services. For more information, visit https://en.novogene.com/.

Contact:
Joyce Peng, Ph.D.
Global Marketing Director
Novogene Corporation
+1-626-222-5584
joyce.peng@novogene.com

Novogene receives the 2017 Innovation and Excellence Award from Corporate LiveWire

We are proud to announce that Novogene and our Founder and CEO Ruiqiang Li have been honored with a 2017 Innovation and Excellence Award from Corporate LiveWire, a UK-based provider of business information to the corporate finance sector. The Innovation & Excellence Awards give recognition to businesses that are transforming their respective industries and the standard-bearers of excellence by continually setting industry trends as well as showing significant advances in terms of innovation and improvement.

The Innovation and Excellence Awards are sponsored by The International Business Innovation Association (InBIA), a global non-profit member network that serves a diverse group of 2,200+ entrepreneurship centers. InBIA helps guide, mentor and develop sustainable entrepreneurial programs in every industry and demographic around the globe. In selecting Novogene and Dr. Li, the judging panel at Corporate LiveWire cited the way Novogene has embraced advanced technology, including its use of Illumina HiSeq and PacBio Sequel systems, as integral to the company’s success. The panel also cited Novogene’s dedication to scientific excellence, customer service, data quality, highly trained team and extensive portfolio of patents and publications as key differentiators for the company.

Full Genomes™ Corporation Collaborates with Novogene to Offer Low-cost Whole Genome Ancestry Test

Comprehensive GenomeGuide now available at $895

January 28, 2015, Rockville, MD and San Diego and Beijing – Full Genomes™ Corporation, the first company to offer a high-resolution and comprehensive Y chromosome test in January 2013, announced today that it is collaborating with Novogene, a leading genomics solution provider with the largest Illumina-based sequencing capacity in China, to offer GenomeGuide , one of the first whole genome tests for ancestry purposes for under $1,000.

GenomeGuide, now available to consumers at $895, includes raw data (BAM file), variant summary reports from SnpEff and VEP that are compatible with third party tools, such as Promethease, autosomal and X-chromosomal variant identification (Variant Call Format) files , and mitochondrial and Y chromosome reports (for males). As with other Full Genomes products, GenomeGuide is intended for ancestry/research-use only, and should not be relied upon for medical or diagnostic purposes.

Novogene, the only Illumina Genome Network partner in China, will deliver high-quality WGS data using the Illumina Hi-Seq X Ten system capable of sequencing up to 18,000 human genomes per year at the lowest cost per genome, and will apply its advanced bioinformatics capabilities and expertise to provide variant analysis.

“The advent of new technology has enabled Full Genomes to offer GenomeGuide, a new whole genome ancestry test which will be the most comprehensive ancestry test on the market today,” stated Justin Loe, CEO of Full Genomes. “Full Genomes is committed to providing responsible and detailed genetic reports to the customer,” he added, “and we are incorporating the latest technology to enable the consumer to receive comprehensive information on their ancestry. With their advanced Illumina technology, outstanding informatics/analysis, and highly responsive and effective support, we are confident that Novogene will deliver the high-quality WGS results our customers expect.”

“We look forward to collaborating with Full Genomes and to helping enable the delivery of this highly cost competitive ancestry research to consumers,” stated Dr. Ruiqiang Li, Founder and Chief Executive Officer of Novogene. “As one of the first companies in the world to purchase Illumina’s HiSeq X Ten in early 2014, we have extensive experience with the system and are uniquely positioned to provide Full Genomes and its customers with the highest quality WGS data.”

About Full Genomes Corporation

Full Genomes incorporated in 2012 for the purpose of making full genomic sequencing for genealogical use available to the general public at a leading price point. Full Genomes introduced Y Elite, a comprehensive (next generation sequencing) of the Y chromosome in 2013 to the genetic genealogy market. Since then, a variety of customers in the U.S. and overseas, as well as a number of institutions have used FGC’s Y chromosome product. Full Genomes’ proprietary DNA analysis capabilities for the Y chromosome have been recognized and have been used for a variety of research projects. Full Genomes has partnered with various vendors and organizations for sequencing and chip development with the goal of advancing new products and DNA services addressing additional markets.

About Novogene

Novogene Bioinformatics Technology Company, Ltd., headquartered in Beijing with branches in the US and UK, is a leading genomics solution provider with cutting edge bioinformatics expertise and the largest Illumina-based sequencing capacity in China. Committed to quality service and scientific excellence, Novogene has achieved rapid growth and industry recognition by working in partnership with diverse healthcare, educational and research institutions around the globe to realize the unlimited potential of the rapidly evolving world of genomics. The company has completed numerous major service projects with findings published by top-ranked journals such as Science and Nature. Novogene is the first company in China to purchase Illumina’s HiSeq X 10 system and is the only Illumina Genome Network partner in China. Novogene Corporation is Novogene’s U.S. subsidiary, based in San Diego, CA. To learn more, visit https://en.novogene.com.

For more information, contact:

Justin Loe
Chief Executive Officer
Full Genomes Corporation
424-333-8537
justin.loe@fullgenomes.com

Joyce Peng, Ph.D.
Global Marketing Director and General Manager
Novogene Corporation
+1-626-222-5584
joyce.peng@novogene.com

Novogene and Illumina to Co-Develop NGS Diagnostic System for Reproductive Health and Oncology Applications

December 14, 2015, Beijing & San Diego — Novogene, a leading global provider of genomic services and solutions, and Illumina, Inc. (NASDAQ: ILMN) today announced they have entered into an agreement to jointly develop advanced clinical applications in the fields of reproductive health and oncology based on next-generation sequencing (NGS) technology. The collaboration signals the increasing importance of genomic applications to improve healthcare in China.

In recent years, NGS technology has evolved rapidly and is regarded as an essential factor for enabling precision medicine. The collaboration between Novogene and Illumina will focus on providing the most advanced and integrated sequencing solutions to the clinical market. In particular, the two companies will work together to develop a user-friendly diagnostic system for clinical prenatal DNA and oncology testing in the Chinese market.

The collaboration will bring together technology from Illumina sequencers with Novogene’s advanced clinical application development capabilities. As part of the agreement, Novogene will provide its nucleic acid extraction, library preparation, and data analysis software, while Illumina will provide NGS instrument components and related reagents.

“As a global provider of high-quality genomic services and leading edge bioinformatics solutions, Novogene is pleased to partner with Illumina to advance the application of NGS technology in precision medicine,” said Dr. Ruiqiang Li, Novogene Founder and Chief Executive Officer. “As the first company in China to purchase Illumina’s HiSeq X Ten System and the largest provider of Illumina-based sequencing capacity in China, Novogene welcomes this opportunity to improve the quality of care enjoyed by the Chinese people.”

“Illumina is very excited to collaborate with Novogene to increase access to genetic sequencing solutions in the fields of reproductive health and oncology testing in China,” said Tim Orpin, General Manager of the Asia Pacific Region for Illumina. “We are committed to partnering with Chinese companies who share our vision of improving human health by unlocking the power of the genome.”

About Novogene

Novogene, headquartered in Beijing with branches in Hong Kong, the U.S. and U.K., is a leading provider of genomic services and solutions with leading edge bioinformatics expertise. Novogene has achieved rapid growth and industry recognition by working in partnership with diverse healthcare, educational and research institutions around the globe to realize the unlimited potential of the rapidly evolving world of genomics. To learn more, visit www.novogene.com.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Forward-Looking Statement for Illumina

This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

For more information, contact:

Novogene
Joyce Peng, Ph.D.
626-222-5584
joyce.peng@novogene.com

or

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com

or

Media:
Jennifer Temple
858-882-6822
pr@illumina.com

Novogene and International Center for Tropical Agriculture to Construct Pan-genome of Cassava

– Novel research approach will unravel the evolutionary history and genetic diversity within the cassava genus and advance cultivation of the world’s third most important food source –

December 3, 2015, San Diego, Beijing, and Cali, Colombia – Novogene, a leading genomics solution provider with the largest Illumina-based sequencing capacity in China, and the International Center for Tropical Agriculture (CIAT), a global agricultural research and development organization and custodian of the world’s largest cassava gene bank, are partnering to construct a pan-genome of cassava (Manihot esculenta) and one of its closest wild relatives (M. e. peruviana). This novel approach to global cassava genome research is designed to unravel the plant’s complex evolutionary history and genetic diversity with the goal of increasing the production and nutritional value of a primary food source in Africa, Latin America and the Caribbean.

Under the pan-genome sequencing project, Novogene will sequence and assemble cassava genomes provided by CIAT from six different eco-geographic zones, and conduct comparative genomic analysis among these genomes in relation to M. e. peruviana. The pan-genome will include the cassava’s core-genome, containing genes present in all of cassava’s ecogeographic zones of domestication (Mesoamerican-Caribbean, Savanna, Andean, South America Lowland Forest, Amazon, Humid Atlantic Forest and Dry Atlantic Forest); the dispensable-genome, containing genes present in two or more ecogeographic zones; and unique genes specific to single ecogeographic adaptation regions, including those from M. e. peruviana.

Since the initial publication of the cassava reference genome, attempts have been made to characterize cassava through genome resequencing to unlock important sources of genetic diversity to improve varieties that will meet future productivity, nutrition and environmental challenges. However, resequencing has often failed to capture many types of structural variation related to agronomic traits, including copy number variation and presence-absence variation, especially for the most genetically diverse lines and the crop’s wild relatives because the reference genome was developed using a single inbred genome. Next-generation sequencing and state-of-the-art assembly algorithms make the construction of pan-genome maps feasible, and the construction of genome maps for individual or multiple strains provides unprecedented opportunities to investigate detailed genetic diversity at the population level.

“This research represents a significant step forward in demonstrating the value of pan-genome de novo assemblies in building and characterizing the genes that pave the path to the domestication of cassava out of the Manihot tribe,” stated Dr. Luis Augusto Becerra Lopez-Lavalle, Cassava Molecular Geneticist at CIAT, “and provides candidate genes for introgression into today’s cassava for crop improvement.” Added Dr Joe Tohme, AgBiodiversity Director of CIAT, “We welcomed the opportunity to partner with Novogene given their high-quality sequencing capabilities, cutting edge bioinformatics technology and expertise, and pan-genomic research experience.”

“Novogene is a pioneer and world leader in the assembly and analysis of pan-genome maps,” stated Dr. Ruiqiang Li, Founder and Chief Executive Officer of Novogene. “Our pan-genomic research studies, including the wild relative of cultivated soybean, have been published in leading scientific journals. We look forward to applying this experience and expertise to the creation of the cassava pan-genome with the objective of enhancing global cultivation of this important food source.”

About Cassava

Cassava is the world’s third most important source of dietary energy after maize and rice. Half-a-billion people in Africa as well as Latin America and the Caribbean depend on this root crop for food, and millions of Asian farmers grow it for industrial markets. Cassava can withstand harsh conditions, making it a key crop for protecting smallholder farming against climate change. Esteemed by smallholder farmers for its tolerance to drought and infertile soils, the crop is inherently eco-efficient, offering a reliable source of food as well as income from markets for a wide variety of food, feed, pharmaceutical and industrial products.

About CIAT

The International Center for Tropical Agriculture (www.ciat.cgiar.org) is a not-for-profit research and development organization dedicated to reducing poverty and hunger while protecting natural resources in developing countries. It is based in Cali, Colombia.

CIAT is part of the CGIAR Consortium, a global partnership that unites organizations engaged in research for a food-secure future. CGIAR research is dedicated to reducing rural poverty, increasing food security, improving human health and nutrition, and ensuring more sustainable management of natural resources. Donors include individual countries, major foundations, and international entities. This project was made possible with the financial support of the Federal Ministry for Economic Cooperation and Development, Germany, with support from the German Society for International Cooperation (GIZ) GmbH.

About Novogene

Novogene Bioinformatics Technology Company, Ltd. (www.novogene.com), headquartered in Beijing with branches in the US and UK, is a leading genomics solution provider with cutting edge bioinformatics expertise and the largest Illumina-based sequencing capacity in China. Committed to quality service and scientific excellence, Novogene has achieved rapid growth and industry recognition by working in partnership with diverse healthcare, educational and research institutions around the globe to realize the unlimited potential of the rapidly evolving world of genomics. The company has completed numerous major service projects with findings published by top-ranked journals such as Science and Nature. Novogene is the first company in China to purchase Illumina’s HiSeq X 10 system and is the only Illumina Genome Network partner in China. Novogene Corporation is Novogene’s U.S. subsidiary, based in San Diego, CA.

For more information, contact:

Luis Augusto Becerra Lopez-Lavalle
Principal Research Scientist and Cassava Molecular Geneticist
Agrobiodiversity Research Area – Cassava Program
International Center for Tropical Agriculture (CIAT)
l.a.becerra@cgiar.org

Joe Tohme
Research Director
Agrobiodiversity Research Area
International Center for Tropical Agriculture (CIAT)
j.tohme2@cgiar.org

Joyce Peng, Ph.D.
Global Marketing Director and General Manager
Novogene Corporation
+1-626-222-5584
joyce.peng@novogene.com

Connect with Novogene at PAG 2016, San Diego, California

Novogene will attend the Plant and Animal Genome Conference XXIV in San Diego, January 9th-13th, 2015. You are invited to visit us at Booth 431 to discuss your NGS needs. To schedule a private business meeting during the conference with our executive team, please contact us at support@novogene.com.

The Plant and Animal Genome Conference (PAG 2016) will be held in San Diego, California this year. As the largest plant and animal genomics meeting and expo worldwide, PAG provides a forum for the presentation and discussion of recent developments and future plans for plant & animal genome projects

Novogene is a genomic services and solutions provider with cutting edge NGS and bioinformatics expertise, and one of the largest sequencing capacities in the world. The company utilizes scientific expertise, a commitment to customer service and unsurpassed data quality to help clients realize their research goals in the rapidly evolving world of genomics. With nearly 1,000 employees, multiple locations around the world, 34 NGS related patents, and >100 publications in top tier journals in just 4 years, the company has rapidly become a world-leader in NGS services.

International Potato Center Announces Partnership with Novogene Bioinformatics Technology to Advance Global Potato Genomics

International Potato Center Announces Partnership with Novogene Bioinformatics Technology to Advance Global Potato Genomics

– Joint research project to sequence 10 new potato genomes with the goal of facilitating production of improved varieties –

July 28, 2015, Lima, Peru and Beijing, China – The International Potato Center (CIP), a global agricultural research and development organization, member of the CGIAR Consortium, and custodian of the world’s largest potato gene bank, is partnering with Novogene Bioinformatics Technology Co., Ltd., a leading genomics solution provider with the largest Illumina-based sequencing capacity in China, to advance potato genome research. Announced at the 9th World Potato Congress being held July 28 – 30 in Beijing, China, the partnership aims to facilitate production of improved varieties that will meet future challenges such as increased yield, disease resistance and drought tolerance in response to global population growth and the effects of climate change on crops.

Under the partnership, Novogene will sequence the genomes of samples provided by CIP from nine different taxa of cultivated potato and one closely related wild species. Novogene’s scientists will then apply their cutting edge bioinformatics technologies and expertise to assemble the millions of sequences and align them to the publically available reference potato genome.

“Our partnership with Novogene has the potential to significantly advance potato genomics and benefit current and future research to improve potato cultivation,” said Dr. Barbara H. Wells, Director General of CIP and a keynote speaker at the World Potato Congress. “At its core, it will enable the sequencing of ten new potato genomes, whilecurrently only two are known. Five years ago, even attempting such a project would not have been feasible. While still no trivial task, the combined knowledge of CIP plant scientists and Novogenescientists along with advances in technology now makes this type of discovery a possibility.”

Dr. David Ellis, Director of CIP’s Genebank, stated, “The work being undertaken represents a large first step to enable us to start to understand the complex genomes of potato. Novogene brings great technological know-how to this project that will help us to unravel hidden genetic treasures in the potato genome and the CIP Genebank. Uncovering and unraveling these treasures – including the possibility of identifying genes that are responsible for important traits such as disease resistance, insect resistance, drought, frost and salinity tolerance, early tuber formation, enhanced yield and more – all becomes possible via the use of genomics technology.

“We are already seeing this come to light in other crops,” added Dr. Ellis. “It is now possible with potato.”

“We welcome this opportunity to partner with the International Potato Center to advance this important genomic research,” stated Dr. Ruiqiang Li, Founder and Chief Executive Officer of Novogene. “By applying our sequencing and bioinformatics expertise to CIP’s extensive gene bank,we hope to have a positive impact on future global crop production.”

About Novogene
Novogene, headquartered in Beijing with branches in Hong Kong, the U.S. and U.K., is a leading genomics solution provider with cutting edge bioinformatics expertise and the largest Illumina-based sequencing capacity in China. Committed to quality service and scientific excellence, Novogene has achieved rapid growth and industry recognition by working in partnership with diverse healthcare, educational and research institutions around the globe to realize the unlimited potential of the rapidly evolving world of genomics. The company has completed numerous major service projects with findings published by top-ranked journals such as Science and Nature series. Novogene is the first company in China to purchase Illumina’s HiSeq X Ten System and is the only Illumina Genome Network partner in China.

About CIP
CIP, headquartered in Lima, Peru, was founded in 1971 as a root and tuber research-for-development institution delivering sustainable solutions to the pressing world problems of hunger, poverty, malnutrition and the degradation of natural resources.  CIP houses the global in-trust potato, sweetpotato and Andean Root and Tuber Crops collections and contains the world’s largest collection of potato diversity.  CIP has regional offices in Peru, Ecuador, Kenya, India and China andis active globally with projects in 30 developing countries across Asia, Africa, and Latin America.

CIP is part of the CGIAR Consortium, a global partnership that unites organizations engaged in research for a food secure future. CGIAR research is dedicated to reducing rural poverty, increasing food security, improving human health and nutrition, and ensuring more sustainable management of natural resources. Donors include individual countries, major foundations, and international entities.

This project was made possible with the financial support of the Federal Ministry for Economic Cooperation and Development, Germany.

For more information, contact:

Joel Ranck
Head of Communications
International Potato Center
+51 1 349 6017 ext 3011
j.ranck@cgiar.org

Joyce Peng, Ph.D.
Global Marketing Director and General Manager
Novogene Corporation
+1-626-222-5584
joyce.peng@novogene.com